Alerta

CELL CULTURED BERRIES AND PRODUCTS DERIVED THEREFROM

Resumen de: AU2024395220A1

The present invention provides culture-derived berry cells compositions which have a high phenolic acid and low anthocyanins in their polyphenolic fraction, and are high in protein, low in sugar, and have a high antioxidation potential.

AUTOMATED INSULIN DELIVERY SYSTEM USING PRAMLINTIDE

Resumen de: US20260174960A1

Disclosed herein are systems and methods for the delivery of insulin and pramlintide using an automated insulin delivery system. In a first embodiment, a drug delivery system is configured to deliver independent doses of insulin and pramlintide. The system monitors the user's blood glucose level and determines when a meal is been ingested and, in response, delivers the dose of pramlintide which, in turn alters the required delivery of insulin. In the second embodiment, the drug delivery system is configured to deliver a co-formulation of insulin and pramlintide as basal doses. The total amount of pramlintide delivered in a most recent pre-determine period of time, for example, 24 hours, is used to alter the aggressiveness of the algorithm which determines the basal doses of the co-formulation.

CONTINUOUS GLUCOSE MONITORING (CGM) DEVICE

Resumen de: WO2026135636A1

This invention relates to medical devices, particularly a continuous glucose monitoring (CGM) device designed for the diagnosis and monitoring of metabolic diseases such as diabetes. The invention offers an innovative monitoring solution for both type 1 diabetes, which arises from insufficient insulin production, and the more common type 2 diabetes, which is associated with insulin resistance. By enabling continuous blood sugar monitoring, the invention provides a user-friendly, eco-friendly, and cost-effective solution for diabetes management. The device allows real-time monitoring of glucose levels and delivers visual, auditory, and vibrational alerts to the user. As a result, it establishes a safer, more practical, and continuous health management system for users.

GLUCOSE ALERT PREDICTION HORIZON MODIFICATION

Resumen de: US20260174399A1

Data describing glucose measurements is received from a continuous glucose monitoring (CGM) system worn by a user and predicted glucose values during a future time period are generated for the user based on the data. A determination is made that at least one of the predicted glucose values satisfies a threshold value for an alert, which is associated with a prediction horizon that defines an amount of time prior to satisfaction of the threshold value for communicating the alert to the user. Output of the alert is caused responsive to determining that the at least one predicted glucose value satisfies the threshold value for the alert within the prediction horizon, relative to a current time. The prediction horizon is modified based on a user response to the alert. Output of a subsequent instance of the alert is caused based on the modified prediction horizon.

SYSTEMS AND METHODS FOR OPTIMIZING MEDICAMENT DOSING

Resumen de: US20260174961A1

A system for monitoring a patient includes one or more processors and a sensor device implemented in circuitry. The system is configured to measure, using the sensor device, a blood glucose status of the patient, and determine, using one or more processors, an initial insulin dose for the patient based on the blood glucose status of the patient. The system is further configured to optimize the initial insulin dose for the patient, based at least in part on a correction factor, to create an optimized insulin dose for the patient. The system is configured to facilitate therapy, using the one or more processors, based on the determined optimized insulin dose.

A METHOD TO GENERATE IMMUNO-FREE AND STRESS-RESISTANT DONOR CELLS

Resumen de: WO2026133193A1

A method for generating immuno-free and stress-resistant donor cells comprising editing PRDM1 and FOXP3 genes in T-cells and B-cells with CRISPR-Cas9 and modulating immune responses to reduce inflammation and prevent autoimmunity. Particularly, the present invention discloses a method for treating Type 1 Diabetes, comprising genetically modifying pancreatic beta cells with CRISPR-Cas9, and altering HLA expression, and upregulating immune checkpoint molecules such as PD-L1 to obtain immune-tolerant and stress-resistant pancreatic beta cells.

SECONDARY HYDROGEL, POSTGRAFT ENANGLEMENT, AND INTERPENETRATING NETWORKS

Resumen de: WO2026136254A1

A sensor (e.g., an analyte sensor) that may be implanted partially or fully within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a housing, a first polymer that includes analyte indicator molecules and covers at least a portion of the housing, and a second polymer that forms an interpenetrating network with the first polymer. The second polymer may prevent biological or protein interference of the sensor.

CANCER SCREENING METHOD

Resumen de: WO2026137021A2

A cancer screening method takes advantage of the Warburg Effect to provide an early detection method and system. The cancer screening method includes administering a glucose solution, such as a C-13 glucose solution, measuring a metabolized lactate level in the blood of the individual after a period of time following the administration of the glucose solution, and comparing the measured lactate level to a baseline lactate level representative of noncancerous activity, and making a determination as to whether or not the measured lactate level is potentially indicative of cancer activity in the individual. The period of time is selected to be an amount of time following the glucose administration after which metabolized lactate from cancerous cells would be present in the blood and before which the metabolized lactate would be cleared or substantial amounts of non-cancerous metabolized lactate would be present in the blood of the individual.

DEVICE FOR DISTRIBUTING AND RECEIVING A HETEROGENEOUS POPULATION OF PANCREATIC CELLS, METHOD AND BIOREACTOR

Resumen de: WO2026131972A1

The invention relates to a device for distributing and receiving a population of pancreatic islets heterogeneous in size, the device comprising a matrix having a first face opposite a second face, characterized in that the matrix comprises concentric channels centered on a center O, the channels have an opening for receiving the pancreatic cells, the opening leading out onto the first face, the opening extending over the entire length (L) of the channel, the opening having a width (I) taken along the section Si, the device being configured such that the widths of the opening of two adjacent channels have an equal or increasing value moving away from the center O and such that the widths of the opening of a channel closest to the center O and of a channel furthest from the center O have an increasing value moving away from the center O. The invention relates to the field of implantable devices, in particular artificial pancreas devices.

IDENTIFYING POTENTIAL ANALYTE SENSOR FAULTS THROUGH INTERACTION WITH AMD SYSTEMS

Resumen de: WO2026136247A1

Presented is a medicament delivery system including a controller, a wearable medication delivery device, an analyte sensor, and other devices. In an example, a receiver is operable to receive glucose measurement values from the analyte sensor. A number of devices of the medicament delivery system may include a processor operable to execute programming code and to identify anomalous readings among the received glucose measurement values. The identified anomalous reading may, for example, be based on the received glucose measurement values violating a measurement change threshold indicative of abnormal sensor behavior. The processor may be operable to, in response to identifying the anomalous reading, revert a medicament delivery setting to a default safety basal delivery setting and/or generate a notification, an inquiry, and/or an alert for presentation to a user.

GLUCOSE SENSOR IDENTIFICATION USING ELECTRICAL PARAMETERS

Resumen de: EP4763078A2

An example method for calibrating a glucose sensor includes determining, by one or more processors, a set of electrical parameters for the glucose sensor of a plurality of glucose sensors and determining, by the one or more processors, a cluster for the glucose sensor based on the set of electrical parameters. Each cluster of the plurality of clusters identifies respective configuration information. In this example, the method includes configuring, by the one or more processors, the glucose sensor to determine a glucose level of a patient based on configuration information identified by the determined cluster.

BLOOD GLUCOSE MANAGEMENT METHOD, USER INTERFACE, AND RELATED APPARATUS

Resumen de: EP4765156A1

A blood glucose management method, a user interface, and a related apparatus are provided. According to the blood glucose management method, a first meal time can be determined based on historical blood glucose values of a user; a second meal time can be determined based on one or more of the following: a meal time input by the user, a hand movement of the user, and a heart rate of the user; and a third meal time can be determined based on the first meal time and the second meal time, where the third meal time is used to evaluate a blood glucose health status of the user. A meal time of the user is predicted based on historical meal times of the user that are determined in a plurality of manners, so that an electronic device can evaluate a blood glucose status of the user more accurately.

CLOSED-LOOP BLOOD GLUCOSE CONTROL SYSTEMS AND METHODS

Resumen de: EP4765154A2

0001 An automated closed-loop blood glucose control system comprises a continuous glucose-monitoring sensor (101), a subcutaneous insulin delivery device (103); and a controller (105) which determines a maximal allowable insulin injection amount and determines an insulin delivery control signal on the basis of the maximal allowable insulin injection amount and the quantity of insulin to inject.

DYNAMIC ADJUSTMENT OF A CORRECTION FACTOR OF A USER BASED ON GLUCOSE VALUES

Resumen de: WO2025038566A1

The exemplary embodiments may provide a correction factor (CF) for a user that is dynamically adjustable based on current glucose level. In some exemplary embodiments, the CF of the user is adjusted based on the current glucose level of the user. As the current glucose level of the user increases to be above a threshold, the CF may be adjusted to reflect a decrease in the insulin sensitivity of the user. This adjustment may cause the control system to increase the amount of insulin delivered to the user as the glucose level of the user exceeds the threshold. Similarly, the CF of the user may be adjusted based on the current target glucose level of the user or based on a combination of the current glucose level of the user and the current target glucose level of the user.

Culture medium for closed culture of mesenchymal stem cells as well as culture method and application of culture medium

Resumen de: CN122256246A

The invention provides a culture medium for closed culture of mesenchymal stem cells. The culture medium comprises the following components: human platelet lysate with the volume concentration of 1%, basic culture medium dry powder with the concentration of 10-15g/L, HEPES with the concentration of 15-20mM, sodium bicarbonate with the concentration of 1.0-2.0 g/L and sodium chloride with the concentration of 0.1-1.0 g/L, wherein the basic culture medium dry powder comprises non-essential amino acid, D-glucose, L-glutamine, specific growth factors, inorganic salt and vitamins. When the culture medium provided by the invention is used for culturing the mesenchymal stem cells, exogenous CO2 is not needed, so that the equipment cost and the process complexity are reduced; in addition, the cell viability is larger than or equal to 97%, particle size distribution is more concentrated, surface marker expression is more stable, and large-scale production is facilitated.

Portable glucometer

Resumen de: CN224387461U

The utility model belongs to the field of glucometers, and particularly relates to a portable glucometer which comprises a glucometer body, a test paper inserting opening is formed in the bottom of the glucometer body, a protective cover is hinged to the bottom of the glucometer body, and the position of the protective cover corresponds to the position of the test paper inserting opening. An opening and closing mechanism is jointly arranged between the protective cover and the glucometer body, a portable belt is fixedly connected to the top of the glucometer body, two buckles are fixedly connected to the right side of the glucometer body, and a blood sampling pen is jointly connected between the two buckles in a clamped mode. According to the blood glucose meter, the two buckles are arranged on the body of the blood glucose meter body, the blood sampling pen is fixed to the body of the blood glucose meter body through the buckles, double protection is achieved through the fixing rope and the silica gel needle head protection sleeve, the loss or pollution risk is greatly reduced, and due to the integrated design of the blood sampling pen and the blood glucose meter body, the blood glucose meter is convenient to use. And the overall portability is further improved.

Freezing preservation solution for semen of Ampelopsis angustifolia, and preparation method and application method thereof

Resumen de: CN122250448A

The invention belongs to the technical field of aquatic product germplasm resource protection and breeding, and particularly relates to a method for collecting, preserving and recovering sperms of Amylabris fishes, in particular to Amylabris sperm cryopreservation liquid and a preparation method and an application method thereof. In order to solve the problems of low collection efficiency, short preservation time and low motility of recovered sperms in the prior art, the cryopreservation liquid for the skinned fish sperms consists of methanol, lecithin, resveratrol and glucose, and the volume is fixed to 1L by using double distilled water. The application method comprises the following steps: 1, semen collection and quality evaluation; 2, preparing a freezing preservation solution for the skinned fish seminal fluid; 3, mixing the seminal fluid with the precooled 4 DEG C skinned fish seminal fluid cryopreservation liquid, sub-packaging, and performing programmed cooling by adopting a four-step method; 4, collecting ova; 5, rewarming the seminal fluid and detecting the activity of the seminal fluid; 6, artificial insemination and incubation. The preservation time of the semen is prolonged from several hours to several years or above, the sperm motility can reach 40% or above through rapid unfreezing, and the fertilization rate can reach 57% or above.

Application of carrot-derived extracellular vesicle-like particles in preparation of skin wound repair product

Resumen de: CN122251458A

The invention provides application of carrot-derived extracellular vesicle-like particles in preparation of a skin wound repair product, and belongs to the technical field of biological medicines. The extracellular vesicle-like particle has good water dispersibility and low-temperature storage stability; the composition can be taken by dermal fibroblasts, vascular endothelial cells and the like, can reduce cell apoptosis, improve cell viability and promote proliferation, migration and vascularization related functions under damage conditions of high glucose, high fat and the like, so that the functions of the dermal fibroblasts and the vascular endothelial cells are synergistically improved, and the composition has a certain antibacterial ability and can be used for preparing a medicine for treating hyperglycemia and hyperlipidemia. Therefore, skin wound healing is facilitated, and a scheme and a clinical transformation thought are provided for wound treatment.

SIP (Session Initiation Protocol) packaging structure applied to glucometer and production process

Resumen de: CN122270193A

The invention relates to an SIP packaging structure applied to a glucometer and a production technology, and relates to the field of glucometers, the SIP packaging structure comprises a multi-layer wiring substrate and a packaging body, the multi-layer wiring substrate is provided with a mounting area used for mounting a functional chip and an interconnection circuit used for realizing electric connection of the chip; the functional chip comprises an MCU chip U2, a storage chip U1, a Bluetooth chip U3, an NFC chip U4 and a power supply chip Q; the MCU chip U2, the storage chip U1, the Bluetooth chip U3, the NFC chip U4 and the power supply chip Q are integrated and installed on the multi-layer wiring substrate. The multilayer wiring substrate is also provided with a crystal oscillator which is used for providing a clock signal for the MCU chip U2. The multi-layer wiring substrate and the chips installed on the multi-layer wiring substrate form a packaging body through injection molding packaging. The blood glucose meter has the advantages that the size of an internal circuit of the blood glucose meter is reduced, the chip is integrally protected through the packaging body, the water tightness and the air tightness of the device are improved, and the reliability of the device is enhanced.

Personalized closed-loop artificial pancreas system

Resumen de: CN122270304A

A personalized closed-loop artificial pancreas system, comprising: a detection module (100) for continuously detecting a blood glucose level of a patient; the infusion module (102) is used for infusing insulin into the body of the patient; the program module (101) is used for controlling the detection module (100) and the infusion module (102), the program module (101) generates an insulin infusion instruction at least according to the blood glucose value detected by the detection module (100) and controls the infusion module (102) to conduct infusion, the program module (101) comprises a user interface, the program module (101) responds to input of a patient, the program module (101) executes a corresponding meal mode function, and the infusion module (102) conducts infusion according to the meal mode function. The meal mode comprises a high-carbon water mode and a normal-carbon water meal mode, the program module (101) executes the function of the high-carbon water mode or the normal-carbon water mode according to the input of a patient, the closed-loop artificial pancreas can be suitable for people with different carbon water consumption habits, the adaptability of the closed-loop artificial pancreas to different people is improved, and the application range of the closed-loop artificial pancreas is widened. And people with different carbon water consumption habits can maintain satisfactory blood sugar control effects.

Nanometer material for targeted driving of recovery of endangered cells as well as preparation method and application of nanometer material

Resumen de: CN122251440A

The invention discloses a nano-material for targeted driving of recovery of an endangered cell as well as a preparation method and application of the nano-material. The nano material is nano platelet vesicles with phosphatidylserine exposed on the outer layer of the membrane after nanocrystallization and centrifugation. The preparation method comprises the following steps: separating and enriching platelets from peripheral blood, then nanocrystallizing the platelets, and inducing phosphatidylserine on a platelet membrane to be everted through high-speed centrifugation. The material is used for preparing a medicine for promoting tissue repair, and tissue repair including repair of orthopedics, muscle, skin, spinal cord or visceral organ tissues, especially repair of diabetic foot, skin avulsion injury, ischemic flap or spinal cord injury is promoted by targeting an endangered cell, enhancing membrane repair capability of the endangered cell and promoting recovery of the endangered cell. Under the condition of not intervening the start of lysis programmed cell death, the recovery of the moire cells is successfully promoted, so that the problems of off-target effect and treatment paradox existing in the current mainstream small-molecule inhibitor strategy are effectively solved.

Microneedle sensor, application thereof and intelligent microneedle closed-loop system

Resumen de: CN122250998A

The invention relates to the technical field of medical instruments, in particular to a microneedle sensor, application thereof and an intelligent microneedle closed-loop system. The microneedle sensor comprises a microneedle working electrode, a microneedle pair electrode and a microneedle reference electrode, the microneedle working electrode comprises a hollow microneedle and a carbon aerogel compound filled in the hollow microneedle; the carbon aerogel compound is prepared from carbon aerogel, mineral oil, glucose oxidase, tetrathiafulvalene and a Nafion solution. The microneedle sensor has high sensitivity (0.0448 mA/(cm < 2 >. MM), a wide linear range (0.25-30 mM) and strong anti-interference characteristic, and can still keep 80% of activity in 5 days. Meanwhile, an intelligent micro-needle closed-loop system is constructed by utilizing a micro-needle sensor, real-time blood glucose monitoring and on-demand administration linkage control are realized, and no tissue inflammation is caused after the system is continuously worn for seven days.

Diabetic nephropathy pathological model based on human-derived renal tubular epithelial cell organoid and construction method and application thereof

Resumen de: CN122256229A

The invention discloses a diabetic nephropathy pathological model based on human-derived renal tubular epithelial cell organoid and a construction method and application thereof, and belongs to the technical field of biomedicine. The construction method comprises the following steps: performing combined induction on renal tubular epithelial cell organoid in a culture medium containing glucose, an advanced glycosylation end product and a tumor necrosis factor-alpha to prepare the diabetic nephropathy pathological model. The diabetic nephropathy pathological model is constructed through combined induction, the model shows the core pathological phenotypes of diabetic nephropathy, including renal tubular epithelial cell marker expression down-regulation, fibrosis marker expression up-regulation, basilar membrane thickening and albumin uptake dysfunction, the construction method is simple and standardized, the construction period is short, and the method is suitable for industrial production. The model has good repeatability and stability, has wide application value in high-throughput screening of traditional Chinese medicine monomers or compound medicines with kidney protection effect, and provides a new platform for mechanism research and treatment strategy development of diabetic nephropathy.

Monitoring sock and method for monitoring foot environment of diabetic foot in real time and medium

Resumen de: CN122250975A

The invention provides a monitoring sock, method and medium for monitoring the foot environment of a diabetic foot in real time, and relates to the field of diabetic feet. The monitoring sock body is provided with a sensing assembly, a processor and a terminal; the processor regularly collects foot sole humidity, foot sole microorganisms, blood sugar data, the stress direction and the stress strength of the foot arch, the stress direction and the stress strength of the heel and the temperature of the instep, and analyzes the exercise intensity of a person according to the stress direction and the stress strength of the foot arch and the stress direction and the stress strength of the heel; judging whether the perspiration function of the person is abnormal or not according to the exercise intensity and the sole humidity of the person; whether the blood supply regulation function is abnormal or not is judged according to the plantar microorganisms, the instep temperature and the blood sugar data; and the abnormal results of the perspiration function and the blood supply regulation function of the personnel are uploaded to the terminal. The abnormal conditions of the feet of the user can be captured earlier, so that the probability and risk of diabetic foot occurrence are reduced.

Integrated safety recovery pen cap for insulin pen and use method

Nº publicación: CN122251740A 23/06/2026

Solicitante:

QINHUANGDAO MATERNAL AND CHILD HEALTH HOSPITAL QINHUANGDAO MATERNAL AND CHILD HEALTH CENTER
\u79E6\u7687\u5C9B\u5E02\u5987\u5E7C\u4FDD\u5065\u9662\uFF08\u79E6\u7687\u5C9B\u5E02\u5987\u5E7C\u4FDD\u5065\u4E2D\u5FC3\uFF09

Resumen de: CN122251740A

The invention discloses an integrated safe recovery pen cap for an insulin pen and a use method, and aims to solve the problems of high pricking injury risk, poor universality and tedious operation in the disassembly and recovery process of an existing insulin needle. The pen cap comprises a pen cap body, a guiding piece and a force unloading piece are coaxially arranged in the pen cap body, the cap top of the pen cap body is in sliding connection with a pen top component with a top block, a telescopic piece with a reset function is arranged between the pen top component and the guiding piece, and a penetrating reinforcing piece is arranged in the circumferential direction of the pen cap body; the guide piece is of a through hole structure with an outer equal-diameter cylinder and an inner truncated cone, and the force unloading piece is of an equal-diameter cylindrical hole structure with an outer truncated cone rotation face and an inner axial anti-skid groove. The device can realize whole-course non-contact disassembly and recovery of insulin needles, is adaptive to needles of different specifications, is high in structural integration level and simple and convenient to operate, and thoroughly avoids the risk of needle injury.